Vertex Reports First Quarter 2024 Financial Results — Product revenue of $2.69 billion, a 13$10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — —Initiated rolling NDA submission for suzetrigine (VX-548) in moderate-to-severe acute pain and on track to complete this quarter — — Entered into agreement to acquire Alpine Immune Sci ...